A Synthesis of (-)-Denopamine

Roger F.C.Brown, W. Roy Jackson and Tom D. McCarthy*

Department of Chemistry, Monash University, Wellington Road, Clayton, 3168, Victoria, Australia.


(Received in UK 2 August 1993)

Abstract: The important cardiac drug, (-)-denopamine, has been synthesised in 68% overall yield from para-allyloxybenzaldehyde via (R)-2-hydroxy-2-[(2-propenyloxy)phenyl]acetontrile

Denopamine (5) is a relatively new¹ β_1 -receptor agonist^{2,3} It is effective in the treatment of congestive heart failure.⁴ by increasing cardiac pumping function (positive inotropic activity) without a significant increase in heart rate.⁴ An advantage of denopamine (5) over other drugs possessing positive inotropic activity is that it can be administered orally and has reduced toxicity.

The active form of denopamine is the (R)-enantiomer, (-)-denopamine (5). The Tanabe Seiyaku Co. Ltd, Japan holds two patents for the preparation of (-)-denopamine (5).^{5,6} Other synthetic approachs to (-)-denopamine (5) have been based on asymmetric reduction of ketone precursors^{7,8} or the chirality has been introduced by microbial reduction of alpha ketoesters.⁹ We now report an asymmetric synthesis of (-)-denopamine (5) in high yield from *para*-allyloxybenzaldehyde.

When *para*-allyloxybenzaldehyde was treated with HCN in the presence of (S,S)cyclo(phenylalanylhistidyl),the Inoue catalyst^{10,11,12}, under conditions described previously by us¹³, using precipitated dipeptide¹⁴, the cyanohydrin (1) was produced in 96% conversion and >98% enantiomeric excess. Recrystallisation of the crude reaction mixture (CH₂Cl₂/light petroleum) gave pure cyanohydrin (1) in 90% yield. The reaction was run several times and worked equally successfully on large (100 mmol) or small (10 mmol) scale. The optical purity of the cyanohydrin (1) is dependent on the reaction temperature. For example, when the reaction was carried out at -2^o for 36h, the cyanohydrin (1) was obtained in 96% conversion but only 30% e.e., 15,16




Brussee *et al* has shown that the protected cyanohydrins can be converted into a series of N-substituted β ethanolamines.¹⁷ Applying these conditions, the cyanohydrin (1) was treated with *tert*-butylchlorodimethylsilane (TBSCI) and imidazole to give the silylether (2) in 97% yield. The silylether (2) was then treated successively with DIBAL and quenched with ammonium bromide in methanol to give the primary imine. Addition of excess 3,4-dimethoxyphenylethylamine led to the more stable secondary imine¹⁸ and NaBH4 reduction gave the silyl protected aminoalcohol (3) in 90% yield in one pot from the silylether (2). There were two advantages in using

R. F. C. BROWN et al.

the TBS protected cyanohydrin (2) instead of the corresponding acetal or TMS protected cyanohydrin. The first is that the TBS group was stable to the aqueous acid quench used in the work up of the reaction. Secondly, the aminoalcohol (3) is essentially insoluble in aqueous acid. Excess 3,4-dimethoxyphenylethylamine can be extracted with aqueous HCl leaving the aminoalcohol (3) in the organic phase. The low solubility of TBSprotected ethanolamines in aqueous HCl has been noted previously.¹⁹ The removal of silyl ethers by LiAIH₄, while not a usual reaction, has been applied by Brussee et al to the deprotection of the silvlethers of aminoalcohols.¹⁹ When the aminoalcohol (3) was treated with LiAlH4 in refluxing THF the allyl ether (4) was obtained in 96% yield. The allyl ether (4) was then deprotected with (PPh3)2PdCl2 and tributyltin hydride²⁰ to give the (-)-denopamine (5) in 88% yield after chromatography. The optical rotation and melting point of this sample were in good agreement with that reported in the literature ($[\alpha]_D$ -28.8, c=1.3, MeOH; m.p. 165-165.5°. Lit.⁹[a]_D -28.3, c=1.1, MeOH, Lit.⁹ m.p. 164-165^o).

In conclusion, the synthesis of homochiral (-)-denopamine (5) has been achieved in five steps from para -allyloxybenzaldehyde in 68% overall yield, with only the final step requiring chromatographic separation.



Acknowledgements: We thank the Australian Research Council (ARC) for financial support.

References and Notes

- Ikeo, T., Nagao, T., Suzuki, T., Yabana, H., Nakajima, H., Jpn J. Pharmacol., 1982, 32, 168P. 1.
- 2. Naito, K., Nagao, T., Otsuka, M., Harigaya, S., Nakajima, H., Jpn J. Pharmacol., 1985, 38, 235.
- Naito, K., Nagao, T., Ono, Y., Otsuka, M., Harigaya, S., Nakajima, H., Jpn J. Pharmacol., 1985, 39, 541. 3.
- Ikeo, T., Nagao, T., Suzuki, T., Yabana, H., Nakajima, H., Jpn J. Pharmacol., 1985, 39, 191. Noguchi, K., Irie, K., Jpn Patent 79 70, 233. Chem . Abstr., 1979, 77, 174995x. 4.
- 5.
- 6. Noguchi, K., Irie, K., Jpn Patent 79 70, 231. Chem . Abstr., 1979, 77, 174996y.
- 7. Umino, N., Iwakuma, T., Itoh, N., Chem. Pharm. Bull., 1979, 27, 1479.
- Corey, E.J., and Link, J.O., J. Org. Chem., 1991, 56, 442. Gu, J.-X., Zu-Yi, L., Guo-Qiang, L., Tetrahedron, 1993, 49, 5803 8.
- 9.
- Tanaka, K., Mori, A., Inoue, J.Org. Chem., 1990, 55,181 and references cited therein. 10.
- 11.
- Jackson, W.R., Javatilake, B.R., Matthews, B.R. Wiltshire, C., Aust. J. Chem., 1988, 41, 203. Jackson, W.R., Jacobs, H.A., Jayatilake, B.R., Matthews, B.R. Wiltshire, C., Aust, J. Chem., 1988, 41, 1697. Brown, R.F.C., Jackson, W.R., McCarthy, T.D., Tetrahedron: Asymmetry, 1993, 4, 205 12.
- 13.
- 14. The dipeptide was precipitated from methanol by the addition of ether; Danda, H., Synlett, 1991, 263.
- The enantiomeric excess of the cyanohydrin (1) was obtained from the ¹H n.m.r. spectra of the derived (R)-Mosher's ester. 15.
- 16. Compound (1) to (4) gave satisfactory ¹H n.m.r., i.r. mass spectra and combustion analysis
- Zandbergen, P., van der Nieuwendijk, A., Brussec, J., van de Gen, A., Tetrahedron, 1992, 48, 3977. 17.
- Brussee, J., and van de Gen, A., Recl. Trav. Chim. Pays-Bas, 1991, 110, 25. 18.
- Brussee, J., Dofferhoff, F., Kruse, C.G. and Van Der Gen, A., Tetrahedron, 1990, 46, 1653. 19.
- 20. Dangles, O., Guibe, F., Balavoine, G., Lavielle, S., Marquet, A., J. Org. Chem., 1987, 52, 4984.